REPROCELL News | Drug Discovery

PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

08 February 2024

REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.

End of 2023 Newsletter

15 December 2023

Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

24 October 2023

REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study

Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform

01 June 2023

REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

09 December 2022

The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.

Building economic resilience and unleashing productivity through digital innovation

09 November 2022

CEO of REPROCELL said his company was among those that had received support from HNCDI to help it develop new approaches to drug development.

REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine

31 August 2022

Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.

Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials

17 August 2022

Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.

Life science after lockdown: SPS returns for 2022

15 August 2022

Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.

REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development

08 March 2022

Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.

REPROCELL spotlights the power of smarter biospecimens in new global publication

21 January 2022

REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

25 October 2021

Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.

REPROCELL highlights the power of human fresh tissue in global publication

05 July 2021

This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

15 March 2021

Hoth Therapeutics has executed a partnership agreement with REPROCELL to assess the effect of its HT-003 therapeutic platform on tissue from IBD donors.

eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations

16 July 2020

Learn more about how eTheRNA's mRNA covid vaccine, developed in partnership with REPROCELL, is designed to be protective against future viral variations.